Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2023-01-04 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed as a 'REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934'. Form 6-K is used by foreign private issuers to report material information to the SEC, often mirroring the information they disclose in their home country. The content is a press release announcing the appointment of a new Chief Medical Officer, dated January 4, 2023. This type of material, non-periodic disclosure by a foreign issuer is generally classified under the broad 'Regulatory Filings' category (RNS) in systems that do not have a specific code for Form 6-K, as it is a general regulatory submission that doesn't fit the more specific categories like 10-K (Annual Report), ER (Earnings Release), or DEF 14A (Remuneration). Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' it is the most appropriate fit for a Form 6-K press release filing.
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Board/Management Information Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 04/01/2023. The content announces a specific corporate event: 'BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer'. This type of announcement, concerning a change in senior management, directly corresponds to the definition of Board/Management Information (MANG). Although it mentions an attached PDF, the primary purpose is the immediate disclosure of the management change, making MANG more specific than a general RPA or RNS.
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed as a 'REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934'. Form 6-K is used by foreign private issuers to report material information to the SEC, often mirroring the information they disclose in their home country. The content is a press release announcing the appointment of a new Chief Medical Officer, dated January 4, 2023. This type of material, non-periodic disclosure by a foreign issuer is generally classified under the broad 'Regulatory Filings' category (RNS) in systems that do not have a specific code for Form 6-K, as it is a general regulatory submission that doesn't fit the more specific categories like 10-K (Annual Report), ER (Earnings Release), or DEF 14A (Remuneration). Since RNS is defined as 'General regulatory announcements and fallback category for miscellaneous filings that do not neatly fit into other specific categories,' it is the most appropriate fit for a Form 6-K press release filing.
2023-01-04 English
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
Board/Management Information Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, dated 04/01/2023. The content announces a specific corporate event: 'BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer'. This type of announcement, concerning changes in senior management, directly corresponds to the definition of Board/Management Information (MANG). Although it mentions an attached PDF, the primary purpose is the immediate disclosure of a management change, making MANG more specific than a general RPA or RNS. The document length is short (1867 chars), but the content is the announcement itself, not just a notice that an announcement exists.
2023-01-04 English
6-K
Regulatory Filings
2022-12-20 English
Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
Regulatory Filings Classification · 98% confidence The document is explicitly titled "FORM 6-K" and is filed with the "SECURITIES AND EXCHANGE COMMISSION" as a "REPORT OF FOREIGN PRIVATE ISSUER". Form 6-K is used by foreign private issuers to report material information that is made public in their home country or that is required to be filed with a stock exchange outside the U.S. This type of filing is generally used for current reports that do not fit neatly into the standard SEC forms (like 10-K or 10-Q). Since the definitions provided do not have a specific code for Form 6-K, and this document contains a press release announcing clinical trial results (which is material information), it falls best under the general category for miscellaneous regulatory announcements that don't match the specific financial report types (10-K, IR, ER, etc.). Therefore, the most appropriate fallback category is Regulatory Filings (RNS). The document length is substantial (12,518 chars), so it is the report itself, not just an announcement of a report (RPA).
2022-12-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.